- Home
- PD vs PTGX Comparison
PD vs PTGX Comparison
Compare PD & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PD | PTGX |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 5.4B |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PD | PTGX |
|---|---|---|
| Price | $12.34 | $81.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $17.50 | ★ $93.00 |
| AVG Volume (30 Days) | ★ 1.7M | 909.6K |
| Earning Date | 11-25-2025 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.63 | 0.72 |
| Revenue | ★ $489,207,000.00 | $209,217,000.00 |
| Revenue This Year | $8.16 | N/A |
| Revenue Next Year | $3.88 | $288.98 |
| P/E Ratio | ★ $7.67 | $114.23 |
| Revenue Growth | ★ 7.01 | N/A |
| 52 Week Low | $11.13 | $33.70 |
| 52 Week High | $20.00 | $96.54 |
Technical Indicators
Market Signals| Indicator | PD | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.53 | 34.18 |
| Support Level | $12.06 | $84.11 |
| Resistance Level | $13.56 | $89.61 |
| Average True Range (ATR) | 0.37 | 3.02 |
| MACD | 0.00 | -1.16 |
| Stochastic Oscillator | 14.69 | 2.52 |
Price Performance
Historical ComparisonAbout PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.